The optimal range of a given blood biomarker is a narrow band of upper and lower limits that correspond to the optimally healthy levels for that biomarker. In contrast to the “normal” reference ranges used in allopathic medicine, the optimal range is meant to reflect optimal health and function health rather than the absence of disease.
Medical practitioners track their patients’ progress towards and away from the optimal range to detect early changes in metabolism and trends towards dysfunction. Optimal ranges provide the practitioner with an opportunity to explore imbalances before they progress into pathology. In this way, practitioners can treat dysfunction before it evolves into a disease. Let’s break down the what and how of the optimal range.
Under allopathic approaches, a practitioner might take one blood test, note that a given biomarker isn’t low or high enough to indicate the presence of disease, and reassure the patient that everything looks normal — even if that patient is still experiencing dysfunction like fatigue, pain or inflammation.
That’s because the broad reference ranges used by the laboratories that analyze blood samples are based on averages, not on actual health. When faced with these broad ranges, a practitioner or a patient might conclude that because a biomarker falls within normal limits, there is no disease and no need for treatment. But relying on these reference ranges when conducting a blood biomarker functional analysis can be a mistake. Where do these reference ranges come from?
To calculate a biomarker range, labs test samples of blood drawn from a certain population with similar characteristics e.g. age, gender, health status, race— for example, a lab might take blood from 150 males between the ages of 40 to 75.
Next, labs assess the levels of the relevant biomarker within that sample and generate a bell curve from the results. In order to determine the upper and lower limit of the reference range (the reference interval), they use 2 points of standard deviation i.e. the upper 2.5% and lower 2.5% of the bell curve are considered "not normal". The remainder represents the range in which 95% of the sampled population’s blood biomarker levels fall. This is defined as “normal.”
However, it should be evident that equating this “normal” biomarker range with a healthy biomarker range is problematic. Consider the fact that the sampled population is essentially a random snapshot, intended to capture the average — not what’s healthy. In many parts of the world, people are obese, exercise less than they should, eat a poor diet, are exposed to pollutants, and more. Average blood biomarker ranges from these populations will wildly misrepresent the optimal health targets patients should be shooting for.
Many practitioners don't consider how the standard blood biomarker ranges are determined. If a practitioner is having a challenging time diagnosing a patients’ complaints, orders a blood test and sees that the results fall within the reference range, they might conclude that there was no useful diagnostic information from the blood test that they ordered and that they need additional, more invasive testing to make a diagnosis — or worse, that the patient is exaggerating their symptoms.
The standard blood biomarker ranges aren’t designed to measure health, but rather where a patient falls in comparison to the average. Understanding this is an essential first step to making better, more impactful assessments and treatment plans.
Using functional or optimal ranges, practitioners can help identify when a patient is trending towards dysfunction and help guide them back to health. The standard reference ranges described above are useful at diagnosing pathology; that is, if some disease is causing a given biomarker to register as excessively high or low, it can serve as a clear sign to practitioners that the patient is suffering from a clinical condition and that their diagnostic thinking was correct.
However, this kind of black-and-white thinking — where the patient is either healthy or sick with a clinical condition — leaves many dysfunctional, unhealthy patients to suffer. Under the functional approach, we use tighter, optimal ranges that represent the ideal level for a given biomarker. When a biomarker strays above or below that range, practitioners can use this as a sign that there is dysfunction and an intervention is needed, whether that’s the prescription of supplements, dietary and lifestyle changes, or any other type of treatment, including pharmaceutical intervention if warranted.
To make even greater use of functional blood chemistry’s optimal ranges, practitioners can track their patient's blood test results over time and observe as biomarkers shift towards or away from the optimal range.
Overview
Using a tighter optimal range to assess and treat dysfunction before it becomes a disease sounds simple enough. But there is a multitude of biomarkers out there, each with different characteristics, interactions, and significance.
To demonstrate what the use of Functional Blood Chemistry Analysis (FBCA) looks like in practice, let's review six representative blood biomarkers:
We'll examine how "normal" levels of these blood biomarkers are often associated with dysfunction and disease and how levels that fall within the optimal range are associated with better patient outcomes. By examining these biomarkers in detail, we can gain a clearer picture of what optimal ranges are and why Functional Blood Chemistry Analysis is the best tool for guiding patients' blood biomarker levels back to healthier levels.
Glucose
Healthy blood glucose levels are an excellent example of why functional ranges are so important. In 1979, patients needed to have a fasting plasma glucose of 140 mg/dl or higher to be diagnosed with diabetes — anything below that level was high but had no diagnostic status. However, if your fasting blood glucose was measured at, say, 140 mg/dL, you’d be at dire risk, at 135 mg/dL, you'd be told to "wait and see". In the past, that risk wasn’t properly recognized. Today, we understand it to be prediabetes.
Medical practitioners of all stripes recognize prediabetes as an important medical condition to be monitored and treated. Current guidelines recognize prediabetes as occurring between 100 and 125 mg/dL, with diabetes beginning at 126 mg/dL and higher. Recognizing this earlier, precursory stage before the relevant condition helps practitioners prevent diabetes from ever occurring in the first place.
But we can actually zoom in even closer and gain even greater impacts on our patients’ health. Current guidelines put the “normal” range at 70 to 99 mg/dL. Yet research suggests that even individuals in the higher portion of that range — from 90 to 99 mg/dL — are significantly more likely to progress to diabetes than those with less than 85 mg/dL.
Current research suggests that we should really be targeting a range of 75 to 86 mg/dL.
Homocysteine
Homocysteine — an amino acid synthesized by the breakdown of other proteins — can be extremely harmful at elevated levels, especially to blood vessels. Under healthy conditions, its levels are kept down by vitamins B6, B12, and folate, which help to process this biomarker.
What constitutes "normal" levels of homocysteine in the blood has varied throughout time, with hyperhomocysteinemia ranging from 15 umol/L to over 100 umol/L. Today, normal homocysteine levels in the blood range from 0 to 21.3 umol/L for individuals over 80 years of age. But again, we find that this range includes the harmless, the worrying, and the outright harmful all at once.
Above 11 umol/L, homocysteine is associated with a significant decline in cognitive function in individuals over 80 years old. The mean level of 10.5 umol/L is associated with atherosclerotic regions in otherwise-healthy individuals’ carotid arteries. Again and again, elevated homocysteine levels are associated with oxidative stress and systemic inflammation, raising the chances for morbidity and mortality. Rather than settle for the normal range of homocysteine at ~10.5 umol/L, a more optimal goal is to shoot for 5-7.2 umol/L.
Iron
Iron-deficient blood is tied to a number of clinical symptoms, yet most of the time, these symptoms appear long after a drop in associated blood biomarker values. In fact, according to the Merck Manual’s stages of iron-deficiency anemia, it’s only at the fifth stage that the physical symptoms of anemia — fatigue, weakness, pallor, and so on — begin to manifest. Even in some of the earlier stages, serum iron and hemoglobin remain within normal limits. Since a low ferritin may be the earliest sign of iron insufficiency, research suggests a low end cut-off of 30 ng/mL. However, researchers suggest that a ferritin below 100 ng/mL may warrant further evaluation of iron insufficiency.
Keeping an eye on the relevant blood biomarkers like serum iron, hemoglobin and ferritin can help practitioners keep their patients well away from serious conditions like anemia.
Thyroid Stimulating Hormone (TSH)
Fluctuations in thyroid-associated biomarkers, such as T4, T3, and thyroid-stimulating hormone (TSH), can serve as important indicators of dysfunction and disease. They also serve as a good example of why focusing on optimal ranges results in better health outcomes than normal ranges.
For example, the upper limit for TSH was once considered to be 10 uIU/mL, until the previous range accepted as “normal” — 4.5 to 9.9 uIU/mL — was revealed to be associated with dyslipidemia, vascular alterations, and diastolic dysfunction in young and middle-aged subjects. Now, the normal range is accepted as 0.45 to 4.5 uIU/mL, but therapeutic targets often aim for 0.3 to 3.0 uIU/mL. Even the higher limits of this reduced range are associated with negative health outcomes like obesity and increased risk for metabolic syndrome. The regular assessment of thyroid biomarkers can help practitioners guide patients away from these undesirable outcomes.
Considering that approximately 95% of healthy individuals maintain a TSH below 2.5 mU/L, and thyroid dysfunction is lowest with a TSH of 1-1.9 mU/L, a range of 1-2 mU/L is considered optimal for TSH. Individuals that fall above or below this optimal range can be further assessed and monitored for thyroid dysfunction before it progresses into metabolic dysfunction.
Vitamin D
Vitamin D plays a huge role in our health, and yet most don’t have optimal vitamin D blood levels. Across the globe, roughly 1 billion people are deficient in vitamin D, and 50% of the world’s population have vitamin D insufficiency.
Vitamin D serves as an excellent example of how optimal blood biomarker levels can create a virtuous cycle for patients: Sufficient levels of vitamin D are associated with reduced levels of potentially worrisome biomarkers like homocysteine, CRP, AST, ALT, and others. But while conventional lab ranges accept 30 to 100 ng/mL as normal, low levels of this critical biomarker affect musculoskeletal health, immune regulation, skin health, cardiovascular integrity, apoptosis, and cell proliferation and differentiation. Vitamin D’s essential role in the body was highlighted during the COVID-19 pandemic when it was found that levels exceeding 30 ng/mL were associated with reduced severity and mortality.
Fortunately, vitamin D is easily accessed through diet, sun exposure, and supplementation; most patients are simply not structuring their diet and lifestyle in a way that meets their vitamin D needs. By prescribing such interventions, we can help patients reach the optimal goal of 50 to 90 ng/mL (or 125 to 225 nmol/L).
Magnesium
Like vitamin D, magnesium plays a crucial role in bodily functions, yet nearly half of the US suffers from magnesium insufficiency. Moreover, subclinical magnesium deficiency is detectable at the reference ranges supplied by major laboratories, which range from 1.5 mg/dL to 2.6 mg/dL.
In fact, research suggests that magnesium blood levels should be kept above 2 mg/dL. When levels dip below that point, patients’ health can suffer, particularly by putting them at increased risk of hypertension.
Overview
Using a tighter optimal range to assess and treat dysfunction before it becomes a disease sounds simple enough. But there is a multitude of biomarkers out there, each with different characteristics, interactions, and significance.
To demonstrate what the use of Functional Blood Chemistry Analysis (FBCA) looks like in practice, let's review six representative blood biomarkers:
We'll examine how "normal" levels of these blood biomarkers are often associated with dysfunction and disease and how levels that fall within the optimal range are associated with better patient outcomes. By examining these biomarkers in detail, we can gain a clearer picture of what optimal ranges are and why Functional Blood Chemistry Analysis is the best tool for guiding patients' blood biomarker levels back to healthier levels.
Glucose
Healthy blood glucose levels are an excellent example of why functional ranges are so important. In 1979, patients needed to have a fasting plasma glucose of 140 mg/dl or higher to be diagnosed with diabetes — anything below that level was high but had no diagnostic status. However, if your fasting blood glucose was measured at, say, 140 mg/dL, you’d be at dire risk, at 135 mg/dL, you'd be told to "wait and see". In the past, that risk wasn’t properly recognized. Today, we understand it to be prediabetes.
Medical practitioners of all stripes recognize prediabetes as an important medical condition to be monitored and treated. Current guidelines recognize prediabetes as occurring between 100 and 125 mg/dL, with diabetes beginning at 126 mg/dL and higher. Recognizing this earlier, precursory stage before the relevant condition helps practitioners prevent diabetes from ever occurring in the first place.
But we can actually zoom in even closer and gain even greater impacts on our patients’ health. Current guidelines put the “normal” range at 70 to 99 mg/dL. Yet research suggests that even individuals in the higher portion of that range — from 90 to 99 mg/dL — are significantly more likely to progress to diabetes than those with less than 85 mg/dL.
Current research suggests that we should really be targeting a range of 75 to 86 mg/dL.
Homocysteine
Homocysteine — an amino acid synthesized by the breakdown of other proteins — can be extremely harmful at elevated levels, especially to blood vessels. Under healthy conditions, its levels are kept down by vitamins B6, B12, and folate, which help to process this biomarker.
What constitutes "normal" levels of homocysteine in the blood has varied throughout time, with hyperhomocysteinemia ranging from 15 umol/L to over 100 umol/L. Today, normal homocysteine levels in the blood range from 0 to 21.3 umol/L for individuals over 80 years of age. But again, we find that this range includes the harmless, the worrying, and the outright harmful all at once.
Above 11 umol/L, homocysteine is associated with a significant decline in cognitive function in individuals over 80 years old. The mean level of 10.5 umol/L is associated with atherosclerotic regions in otherwise-healthy individuals’ carotid arteries. Again and again, elevated homocysteine levels are associated with oxidative stress and systemic inflammation, raising the chances for morbidity and mortality. Rather than settle for the normal range of homocysteine at ~10.5 umol/L, a more optimal goal is to shoot for 5-7.2 umol/L.
Iron
Iron-deficient blood is tied to a number of clinical symptoms, yet most of the time, these symptoms appear long after a drop in associated blood biomarker values. In fact, according to the Merck Manual’s stages of iron-deficiency anemia, it’s only at the fifth stage that the physical symptoms of anemia — fatigue, weakness, pallor, and so on — begin to manifest. Even in some of the earlier stages, serum iron and hemoglobin remain within normal limits. Since a low ferritin may be the earliest sign of iron insufficiency, research suggests a low end cut-off of 30 ng/mL. However, researchers suggest that a ferritin below 100 ng/mL may warrant further evaluation of iron insufficiency.
Keeping an eye on the relevant blood biomarkers like serum iron, hemoglobin and ferritin can help practitioners keep their patients well away from serious conditions like anemia.
Thyroid Stimulating Hormone (TSH)
Fluctuations in thyroid-associated biomarkers, such as T4, T3, and thyroid-stimulating hormone (TSH), can serve as important indicators of dysfunction and disease. They also serve as a good example of why focusing on optimal ranges results in better health outcomes than normal ranges.
For example, the upper limit for TSH was once considered to be 10 uIU/mL, until the previous range accepted as “normal” — 4.5 to 9.9 uIU/mL — was revealed to be associated with dyslipidemia, vascular alterations, and diastolic dysfunction in young and middle-aged subjects. Now, the normal range is accepted as 0.45 to 4.5 uIU/mL, but therapeutic targets often aim for 0.3 to 3.0 uIU/mL. Even the higher limits of this reduced range are associated with negative health outcomes like obesity and increased risk for metabolic syndrome. The regular assessment of thyroid biomarkers can help practitioners guide patients away from these undesirable outcomes.
Considering that approximately 95% of healthy individuals maintain a TSH below 2.5 mU/L, and thyroid dysfunction is lowest with a TSH of 1-1.9 mU/L, a range of 1-2 mU/L is considered optimal for TSH. Individuals that fall above or below this optimal range can be further assessed and monitored for thyroid dysfunction before it progresses into metabolic dysfunction.
Vitamin D
Vitamin D plays a huge role in our health, and yet most don’t have optimal vitamin D blood levels. Across the globe, roughly 1 billion people are deficient in vitamin D, and 50% of the world’s population have vitamin D insufficiency.
Vitamin D serves as an excellent example of how optimal blood biomarker levels can create a virtuous cycle for patients: Sufficient levels of vitamin D are associated with reduced levels of potentially worrisome biomarkers like homocysteine, CRP, AST, ALT, and others. But while conventional lab ranges accept 30 to 100 ng/mL as normal, low levels of this critical biomarker affect musculoskeletal health, immune regulation, skin health, cardiovascular integrity, apoptosis, and cell proliferation and differentiation. Vitamin D’s essential role in the body was highlighted during the COVID-19 pandemic when it was found that levels exceeding 30 ng/mL were associated with reduced severity and mortality.
Fortunately, vitamin D is easily accessed through diet, sun exposure, and supplementation; most patients are simply not structuring their diet and lifestyle in a way that meets their vitamin D needs. By prescribing such interventions, we can help patients reach the optimal goal of 50 to 90 ng/mL (or 125 to 225 nmol/L).
Magnesium
Like vitamin D, magnesium plays a crucial role in bodily functions, yet nearly half of the US suffers from magnesium insufficiency. Moreover, subclinical magnesium deficiency is detectable at the reference ranges supplied by major laboratories, which range from 1.5 mg/dL to 2.6 mg/dL.
In fact, research suggests that magnesium blood levels should be kept above 2 mg/dL. When levels dip below that point, patients’ health can suffer, particularly by putting them at increased risk of hypertension.
Explore our Biomarker Guide for clear and practical insights into your patient’s blood test results. This guide offers an overview of biomarkers and their Optimal Ranges, along with links to detailed blog posts for further understanding. It also includes a curated selection of research papers, providing a well-rounded resource to enhance your Functional Blood Chemistry Analysis knowledge.
Naturally, no individual blood-based biomarker can provide a practitioner with the whole picture of their patients’ health. As an example, you can explore our series on endothelial dysfunction — under this condition, biomarkers like homocysteine and glucose will be elevated while biomarkers like testosterone and adiponectin will be diminished. This pattern of blood-based biomarker change is distinct from, say, that created by a condition like prediabetes — both involve elevated glucose, but the whole of the biomarker landscape looks different in endothelial dysfunction than it does in prediabetes.
Thus, functional practitioners must examine a matrix of biomarkers in order to accurately assess their patients’ health.
An estimated 60-70% of medical decisions are based on laboratory results and interpretation. But as clarified by the examples above, practitioners using the allopathic approach may be making decisions for their patients far too late to prevent certain conditions.
This doesn’t mean that functional practitioners should abandon the use of blood tests as a diagnostic tool; rather, functional practitioners should approach blood testing in the same way they’ve been trained to approach medicine as a whole — functionally.
Using the tighter, optimal ranges for a given biomarker enables functional practitioners to detect the risk of and progression towards a number of undesirable conditions, including:
Functional Blood Chemistry Analysis serves as a complement to other functional assessments. By tracking changes in blood chemistry in combination with an individual’s clinical presentation and symptoms over time, practitioners gain a powerful method of more rapidly identifying dysfunction before it becomes disease and monitoring the impact of their treatment plans.
For many medical practitioners, taking a functional approach to blood chemistry analysis is a novel technique. It could be that your discipline doesn’t traditionally focus on blood chemistry analysis, such as naturopathy or osteopathy. Or, it could be that you’re familiar with blood chemistry analysis, but focusing on functional ranges is new to you.
Medical practitioners that want to learn more about the fundamentals of functional blood chemistry analysis and how to implement it in their practice could benefit from our Functional Blood Chemistry Analysis (FBCA) Mastery Training. Registrants will:
Learning about blood biomarkers and how they can expedite your diagnostic process is an incredible opportunity to enhance your practice. Sign up for the FBCA Mastery Training today and begin learning how to drastically improve your patients’ outcomes.
If you’re still curious about how FBCA works, check out our page, About Blood Chemistry. After all, as medical practitioners, knowledge is the best tool in our toolkit to fight against disease and dysfunction.